匹多莫德治疗过敏性鼻炎临床观察

Clinical Observation of Pidotimod in Treatment of Patients with Rhinallergosis

目的探讨匹多莫德对过敏性鼻炎患者外周血清中Th1/Th2细胞因子表达的影响及其疗效。方法选取2012年3月—2014年7月收治的过敏性鼻炎140例,随机分为观察组和对照组,每组70例。两组均给予基础治疗加鼻腔冲洗,观察组在此基础上给予口服匹多莫德治疗。观察两组治疗前后外周血清中Th1/Th2细胞因子表达变化情况及临床疗效。结果两组治疗后血清白介素-4(IL-4)、IL-5浓度低于治疗前,且观察组低于对照组(P<0.05,P<0.01);两组治疗后血清肿瘤坏死因子-α(TNF-α)、IL-12浓度高于治疗前,且观察组高于对照组(P<0.05,P<0.01)。两组治疗后临床症状及体征评分低于治疗前,且观察组低于对照组,观察组伴随症状恢复时间明显短于对照组(P<0.05,P<0.01)。观察组总有效率高于对照组(P<0.01)。两组不良反应发生率比较差异无统计学意义(P>0.05)。结论在基础治疗的同时给予口服匹多莫德能进一步改善过敏性鼻炎患者的Th1/Th2细胞因子失衡,并能提高临床疗效,缩短伴随症状恢复时间。

Objective To investigate the effect of Pidotimod on expressions of Thl/Th2 eytokines in peripheral serum of patients with rhinallergosis and its clinical efficacy. Methods A total of 140 patients with rhinallergosis admitted during March 2012 and July 2014 were randomly divided into observation group （n = 70） and control group （n = 70）. All the patients underwent basal treatment and nasal douche, and the observation group was added with Pidotimod. The expressions of Th1/Th2 cytokines and clinical efficacy were observed and compared in the two groups before and after the treatment. Results After the treatment, the concentrations of serum interleukin-4 （IL-4） and interleukin-5 （IL-5） in the two groups were significantly lower than those before the treatment, and the concentrations in the observation group were significantly lower than those in the control group （ P 〈 0. 05, P 〈 0. 01 ） ; the concentrations of serum tumor necrosis factor-α （TNF-α） and interleukin-12 （IL-12） in the two groups were significantly higher than those before the treatment, and the concentrations in the observation group were significantly higher than those in the control group （P 〈 0.05, P 〈 0.01 ）. After the treatment, the scores of clinical symptoms and signs in the two groups were significantly lower compared with those before the treatment, and the scores in the observation group were significantly lower compared with those in the control group, and the recovery time of accompanied symptoms in the observation group was significantly shorter than that in the control group （P 〈 0. 05, P 〈 0. 01 ）. The total effective rate in the observation group was significantly higher than that in the control group （P 〈 0. 01 ）. There was no significant difference in incidence rates of adverse effect between the two groups （P 〉 0. 05 ）. Conclusion The basal treatment combined with oral Pidotimod can further improve the disequilibrium of Thl/Th2 cytokines, raise clinical effective rate and shorten the recovery time of accompanied symptoms in patients with rhinallergosis.